Patients with smouldering or asymptomatic multiple myeloma (SMM) are not treated until symptomatic disease develops. SMM is characterised by a serum monoclonal protein component of 3 g/dL or plasma cell infiltration into bone marrow of 10% or more.
|Number of pages||2|
|Journal||Journal of Pharmacy Practice and Research|
|Publication status||Published - 2013|